Marshall, Gerstein & Borun LLP

Partner

Mark H. Izraelewicz is a partner at Marshall, Gerstein & Borun LLP. He recently led CureVac’s U.S. litigation strategy in its high-profile mRNA patent dispute against Pfizer and BioNTech concerning COVID-19 variant-adapted vaccines and related manufacturing technology, culminating in a global resolution announced in August 2025. Under the agreements, CureVac and GSK received a $740 million payment plus single-digit royalties on U.S. COVID-19 vaccine sales going forward. Mark has tried cases as first-chair trial counsel and argued appeals to the Federal Circuit, delivering winning results for life-sciences innovators.

Mark’s success is rooted in a deep scientific background in synthetic organic chemistry and experience prosecuting patent applications. He has represented clients including Spectrum Pharmaceuticals in a series of litigations and at trial, including as first-chair trial counsel in a January 2015 bench trial and subsequent appeal involving Spectrum’s oncology drug Fusilev®. Mark’s training includes an M.S. in chemistry, cutting-edge research at The Scripps Research Institute, and applied work at Abbott Laboratories.

• The University of Chicago Law School (J.D.)
• University of California, San Diego (M.S.)
  • Chemistry
• State University of New York, Buffalo (B.S.)
  • Biochemistry